This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Anderson, J. L. Articles by Muhlestein, J. B. Search for Related Content PubMed PubMed Citation Articles by Anderson, J. L. Articles by Muhlestein, J. B. Social Bookmarking                         What's this?

Cardiovascular Pharmacogenomics: Current Status, Future Prospects

Division of Cardiology, LDS Hospital, 8th Avenue and C Street, Salt Lake City, Utah 84143

John F. Carlquist, PhD

Benjamin D. Home, MPH

Joseph B. Muhlestein, MD

Intermountain Heart Collaborative Research Group, LDS Hospital Cardiovascular Department, and University of Utah School of Medicine, Salt Lake City, Utah

Pharmacogenomics is a field dedicated to exploring the contribution of genetics to interindividual variability in drug response. A goal of cardiovascular pharmacogenomics is to guide cardiovascular drug development and selection so as to optimize therapeutic benefit and minimize the potential for toxicity. Genetic-based differences in drug metabolism have long been recognized but just now are on the verge of wider clinical application. Differences in efficacy of cardiovascular drugs (independent of drug concentration) based on common genetic variations (polymorphisms) only recently have begun to be explored, but the potential for clinical application appears promising. Examples are presented of important pharmacodynamic effects of genetic variants on several drugs, including those in antiarrhythmic, reninangiotensin, f-blocker, lipid-lowering, and antithrombotic classes. Principles of pharmacogenomics applied to drug metabolism are discussed that are relevant to drug development and clinical use, and examples are given for CYP450 phase I enzymes, phase II enzymes, and drug transporters. Challenges in establishing true pharmacogenetic associations are discussed, and current and future clinical potential is summarized. Rapid research progress and initial clinical applications with pharmacogenomics are foreseen in the near future.

Key Words: pharmacogenomics • pharmacogenetics

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 8, No. 1, 71-83 (2003)
DOI: 10.1177/107424840300800i110


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. D. Horne and J. L. Anderson Irrelevance of the Chromosome 9p21.3 Locus for Acute Cardiovascular Events and Restenosis J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1156 - 1157. [Full Text] [PDF]

				J. L. Anderson, B. D. Horne, S. M. Stevens, A. S. Grove, S. Barton, Z. P. Nicholas, S. F.S. Kahn, H. T. May, K. M. Samuelson, J. B. Muhlestein, et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation Circulation, November 27, 2007; 116(22): 2563 - 2570. [Abstract] [Full Text] [PDF]

				B. D. Horne, N. J. Camp, J. L. Anderson, C. P. Mower, J. L. Clarke, M. J. Kolek, J. F. Carlquist, and for the Intermountain Heart Collaborative Study Gr Multiple Less Common Genetic Variants Explain the Association of the Cholesteryl Ester Transfer Protein Gene With Coronary Artery Disease J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2053 - 2060. [Abstract] [Full Text] [PDF]

				C. Kaymak, N. A. Kocabas, E. Durmaz, and D. Oztuna {beta}2 Adrenoceptor (ADRB2) Pharmacogenetics and Cardiovascular Phenotypes during Laryngoscopy and Tracheal Intubation International Journal of Toxicology, November 1, 2006; 25(6): 443 - 449. [Abstract] [Full Text] [PDF]

				J. L. Anderson and J. F. Carlquist Cytokines, Interleukin-18, and the Genetic Determinants of Vascular Inflammation Circulation, August 2, 2005; 112(5): 620 - 623. [Full Text] [PDF]

				H. W. Mohrenweiser Genetic Variation and Exposure Related Risk Estimation: Will Toxicology Enter a New Era? DNA Repair and Cancer as a Paradigm Toxicol Pathol, January 1, 2004; 32(1_suppl): 136 - 145. [Abstract] [PDF]

				J. L. Anderson and J. F. Carlquist Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: Do they add up yet? J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1990 - 1993. [Full Text] [PDF]